 |
|
Mayo Genomic Discovery: Protecting Kidney Function During Heart Failure
June 16, 2009ROCHESTER, Minn. - Mayo Clinic cardiology researchers have found a peptide that helps preserve and improve kidney function during heart failure, without affecting blood pressure. Earlier variations of this peptide caused blood pressure to drop limiting the potential benefits to the kidneys. The findings appear in the current Proceedings of the National Academy of Sciences.
"Heart failure itself and some of the approaches used to treat it can have detrimental effects on the kidneys," says Mayo cardiologist and lead researcher Robert Simari, M.D. "Our hope is that this compound will help protect kidney function while you're being treated, and possibly shorten your hospital stay and keep you out of the hospital."
This new peptide (a unique link of amino acids) has been tested in the laboratory and in animal models and is expected to move into clinical trials next year.
"One of the biggest additional concerns for patients with heart failure is the health of their kidneys," says Dr. Simari. "The extreme case is that it can lead to the kidneys shutting down completely." Nearly 5 million Americans are living with heart failure, a condition where the heart can't pump enough blood to meet the body's needs. Symptoms include shortness of breath, exercise intolerance and fluid retention. All can occur when heart function is impaired.
Seven Years of Research The mapping of the human genome (2000-2003) revealed a gene that produces a protein called BNP (B-type natriuretic peptide). BNP was not only useful in diagnosing heart problems, it also proved therapeutic in treating heart failure. Unfortunately, says Dr. Simari, it had limited use because many heart failure patients experience low blood pressure and BNP lowered it further.
The Mayo investigators discovered an alternative splicing (AS) of BNP in messenger RNA (produced by the same gene). When they shortened the amino acid sequence of ASBNP for testing, they found that it had the same therapeutic benefits as BNP, but without the side effects to blood pressure. Positive impacts include increasing the kidney filtration rate, suppressing harmful protein production, and keeping water and salt flowing from the body. Potentially, this new drug would be given by IV to patients who are being treated in the hospital.
"There's an important reduction of kidney function every time one of these acute heart failure episodes happens," says Dr. Simari. "And by stopping one or more of those decrements, we hope there will be an overall improvement in long-term maintenance of kidney function."
Others on the team include Shuchong Pan, M.D., Ph.D., Horng Chen, M.D., Guido Boerrigter, M.D., Candace Lee, Laurel Kleppe, Amir Lerman, M.D., Margaret Redfield, M.D., John Burnett, Jr., M.D., all from Mayo Clinic, and Deborah Dickey, Ph.D., Jennifer Hall, Ph.D., and Lincoln Potter, Ph.D., all from the University of Minnesota. The research was funded by Mayo Clinic, the National Institutes of Health, and Anexon, Inc.
Mayo Clinic and five of the investigators associated with this research have a financial interest in the technology studied in the research. In accordance with the Bayh-Dole Act, that technology has been licensed to Anexon. Mayo Clinic and Drs. R. Simari and Dr. S. Pan have received royalties from the licensing of that technology of greater than the federal threshold for significant financial interest. Drs. J.Burnett, M.Redfield and H.Chen have received royalties less than the federal threshold for significant financial interest. In addition, Mayo Clinic holds an equity position in Anexon.
Mayo Clinic
"One of the biggest additional concerns for patients with heart failure is the health of their kidneys," says Dr. Simari. "The extreme case is that it can lead to the kidneys shutting down completely." Nearly 5 million Americans are living with heart failure, a condition where the heart can't pump enough blood to meet the body's needs. Symptoms include shortness of breath, exercise intolerance and fluid retention. All can occur when heart function is impaired.
Seven Years of Research The mapping of the human genome (2000-2003) revealed a gene that produces a protein called BNP (B-type natriuretic peptide). BNP was not only useful in diagnosing heart problems, it also proved therapeutic in treating heart failure. Unfortunately, says Dr. Simari, it had limited use because many heart failure patients experience low blood pressure and BNP lowered it further.
The Mayo investigators discovered an alternative splicing (AS) of BNP in messenger RNA (produced by the same gene). When they shortened the amino acid sequence of ASBNP for testing, they found that it had the same therapeutic benefits as BNP, but without the side effects to blood pressure. Positive impacts include increasing the kidney filtration rate, suppressing harmful protein production, and keeping water and salt flowing from the body. Potentially, this new drug would be given by IV to patients who are being treated in the hospital.
"There's an important reduction of kidney function every time one of these acute heart failure episodes happens," says Dr. Simari. "And by stopping one or more of those decrements, we hope there will be an overall improvement in long-term maintenance of kidney function."
Others on the team include Shuchong Pan, M.D., Ph.D., Horng Chen, M.D., Guido Boerrigter, M.D., Candace Lee, Laurel Kleppe, Amir Lerman, M.D., Margaret Redfield, M.D., John Burnett, Jr., M.D., all from Mayo Clinic, and Deborah Dickey, Ph.D., Jennifer Hall, Ph.D., and Lincoln Potter, Ph.D., all from the University of Minnesota. The research was funded by Mayo Clinic, the National Institutes of Health, and Anexon, Inc.
Mayo Clinic and five of the investigators associated with this research have a financial interest in the technology studied in the research. In accordance with the Bayh-Dole Act, that technology has been licensed to Anexon. Mayo Clinic and Drs. R. Simari and Dr. S. Pan have received royalties from the licensing of that technology of greater than the federal threshold for significant financial interest. Drs. J.Burnett, M.Redfield and H.Chen have received royalties less than the federal threshold for significant financial interest. In addition, Mayo Clinic holds an equity position in Anexon.
Mayo Clinic
Heart Failure Current Events and Heart Failure News RSSMount Sinai researchers are the first to identify heart abnormalities in World Trade Center workers
Researchers from Mount Sinai School of Medicine are presenting more than 20 ground-breaking studies at the American College of Cardiology (ACC) 59th annual scientific session (ACC.10) in Atlanta.
As Girth Grows, Risk of Sudden Cardiac Death Shrinks
Obesity has long been identified as a risk factor for cardiovascular disease and heart failure. But, a new study conducted by researchers at the University of Rochester Medical Center found that being skinny confers no advantage when it comes to the risk of dying suddenly from cardiac causes.
Researchers discover chemical that may protect hearts of muscular dystrophy patients
Researchers at the University of Minnesota Medical School have discovered a chemical that may, over the long term, protect the hearts of Duchenne muscular dystrophy patients - a fatal and most common form of muscular dystrophy in children.
Research points to way to improve heart treatment
Current drugs used to treat heart failure and arrhythmias (irregular heartbeat) have limited effectiveness and have side effects.
A full house raises risk of hospital deaths
Admission to a hospital when most of the beds are already full can be deadly for patients, according to a new University of Michigan Health System study showing high occupancy increases the risk of dying in the hospital by 5.6 percent.
Transcendental Meditation activates default mode network, the brain's natural ground state
A new EEG study conducted on college students at American University found they could more highly activate the default mode network, a suggested natural "ground state" of the brain, during their practice of the Transcendental Meditation technique.
Beta blocker therapy underused in heart failure patients
New Saint Louis University research has found that beta blockers, a class of drugs used to prevent the progression of heart failure and manage arrhythmias (irregular heart beat) and hypertension (high blood pressure), are underused in heart failure patients who receive implantable cardiac devices.
Safety data favor norepinephrine over dopamine for shock
Physicians treating patients with shock should consider norepinephrine instead of dopamine as a tool for stabilizing blood pressure, according to an editorial in the March 4, 2010, issue of the New England Journal of Medicine (NEJM).
Cluster of 'critical' follow-up evaluations may improve outlook for hospitalized HF patients
Heart failure is by far the most prevalent chronic cardiac condition. Around 30 million people in Europe have heart failure and its incidence is still increasing: more cases are being identified, more people are living to an old age, and more are surviving a heart attack but with damage to the heart muscle.
Bone marrow cell transplants to benefit those with heart disease
Two studies published in the latest issue of Cell Transplantation (18:12) may lead to new treatments for the treatment of heart diseases.
More Heart Failure Current Events and Heart Failure News Articles
 |
Success with Heart Failure (mass mkt ed): Help and Hope for Those with Congestive Heart Failure by Marc Silver (Author) Up-to-date information on available and forthcoming medical and surgical treatments. How attitude and emotion affect heart failure--and what you can do to stay positive. Tips for adopting a heart-healthy diet and lifestyle. Ways to forge a positive working relationship with your doctor or cardiologist. |
 |
Heart Failure: Pathophysiology, Molecular Biology, and Clinical Management (HEART FAILURE: PATHOPHYSIOLOGY, MOLEC BIOL & CLIN MGT) by Arnold M Katz (Author), Marvin A Konstam (Author) This Second Edition of Dr. Katz's highly acclaimed text has been thoroughly revised to incorporate the latest advances in the study and treatment of heart failure. The book explains the pathophysiology, molecular mechanisms, clinical manifestations, and therapy of heart failure in an integrated, reader-friendly manner that is accessible to both clinicians and basic scientists. More than 100 illustrations, most created for this book by the authors, complement the text. This edition has been completely reorganized. Chapters describe the hemodynamic basis for the clinical manifestations of heart failure; the neurohumoral responses in heart failure and key signaling pathways that mediate functional responses; the proliferative responses in failing hearts; the cellular and molecular... |
 |
The Cleveland Clinic Guide to Heart Failure (Cleveland Clinic Guides) by Randall Starling (Author) Expert medical advice from the #1 heart center in America for 14 years in a row For the 5 million people with heart failure, there’s new reason for hope: recent medical advances have revolutionized how this condition is managed. In The Cleveland Clinic Guide to Heart Failure, Dr. Randall Starling, one of the foremost authorities on heart health, provides authoritative advice to help people survive heart failure and enjoy a good quality of life. This comprehensive resource gives readers the cutting-edge medical guidance Dr. Starling offers his patients, including: Insight into what causes heart failureThe latest breakthrough studies – and what those discoveries mean for the future of this diseaseReliable guidance on diagnostic tests and treatment optionsPersonal stories of... |
|
Heart Failure: A Critical Inquiry into American Medicine and the Revolution in Heart Care by Thomas J. Moore (Author) | |
 |
100 Questions & Answers About Congestive Heart Failure by Campion Quinn (Author) Whether you or a loved one has been diagnosed with congestive heart failure, the number and type of diagnosis and treatment options can be overwhelming. This invaluable resource offers the guidance and advice you need. Written by a prominent physician and by a leader in patient support for this devastating disease, 100 Questions & Answers About Congestive Heart Failure gives you authoritative, practical answers to your questions, including causes, diagnosis, treatment options, quality of life, care giving, sources of support, and much more. |
 |
Cardiac Disorders: Heart Failure (116) CD-ROM by Concept Media, a division of Jobson Medical Information LLC 4 CD series including these programs: [116.1] Heart Failure: Part One; [116.2] Heart Failure: Part Two; ; and instructor's guides in PDF format and self-grading description |
 |
Heart Failure: A Practical Approach to Treatment by William Abraham (Author), Henry Krum (Author) The definitive one-stop guide to treating -- and preventing -- heart failure This practical reference provides all the expert guidance and up-to-the-minute clinical perspectives you need to diagnose, treat, and manage patients with heart failure. A major focus of the book is integration of various management approaches to maximize patient benefit. Coverage begins with a brief introduction to the incidence and causes of heart failure, then quickly moves into a more thorough clinical overview of symptom evaluation, pharmacologic and non-pharmacologic treatment methods, hospitalization, surgical treatments, and more. Features: Clear, step-by-step coverage of prevention and all treatment modalities with evidence-based recommendations Full... |
 |
Congestive Heart Failure Awareness Ribbon Mouse Pad by MyHeritageWear.com The Congestive Heart Failure Ribbon proudly displayed on a mouse pad. There is no better way to achieve awareness for the meaning of the Congestive Heart Failure Ribbon than to display it on your mouse pad for everyone to see. The mouse pad measures at 9.25 x 7.75, it is machine washable, and the colors will not fade or run. Start gaining awareness today by presenting your Congestive Heart Failure Ribbon mouse pad at work or at home. It is certain to keep your mouse rolling in style all while gaining support and awareness! |
 |
Congestive Heart Failure (Have A Heart Series) Also With: Mark Baer (Producer), Dr. Gerry Maddoux (Writer) Believe it or not, congestive heart failure is the most common admitting diagnosis to the hospital in the 65-and-older population. It is due to one or several abnormalities of the heart or blood vessels, causing water to be pushed into the tissues, including the air pockets of the lungs. Most of these conditions can be prevented. Almost all can be effectively treated. If so, why is it the most prevalent admission diagnosis to the hospital as we age? Because doctors h ave precious little time to properly educate you, the patient, about what to avoid, what to look for, and how to live comfortably with this problem. This product is manufactured on demand using DVD-R recordable media. Amazon.com's standard return policy will apply. |
![Heart Failure [Explicit]](http://ecx.images-amazon.com/images/I/51YJsKb2afL._SL160_.jpg) |
Heart Failure [Explicit] Mani Dots (Primary Contributor) |
| © 2010 BrightSurf.com |